Strs Ohio increased its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 12.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,665,197 shares of the biopharmaceutical company’s stock after buying an additional 186,698 shares during the period. Strs Ohio owned 0.10% of Bristol-Myers Squibb worth $122,475,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in the company. Smith Asset Management Group LP boosted its stake in Bristol-Myers Squibb by 439.4% in the second quarter. Smith Asset Management Group LP now owns 990,710 shares of the biopharmaceutical company’s stock worth $72,867,000 after buying an additional 807,050 shares during the period. HL Financial Services LLC boosted its stake in Bristol-Myers Squibb by 0.8% in the second quarter. HL Financial Services LLC now owns 360,221 shares of the biopharmaceutical company’s stock worth $26,494,000 after buying an additional 2,901 shares during the period. Investment House LLC boosted its stake in Bristol-Myers Squibb by 8.9% in the second quarter. Investment House LLC now owns 66,444 shares of the biopharmaceutical company’s stock worth $4,887,000 after buying an additional 5,450 shares during the period. Pitcairn Co. boosted its stake in Bristol-Myers Squibb by 17.2% in the second quarter. Pitcairn Co. now owns 57,970 shares of the biopharmaceutical company’s stock worth $4,264,000 after buying an additional 8,510 shares during the period. Finally, Mount Vernon Associates Inc. MD boosted its stake in Bristol-Myers Squibb by 1.5% in the second quarter. Mount Vernon Associates Inc. MD now owns 19,868 shares of the biopharmaceutical company’s stock worth $1,461,000 after buying an additional 300 shares during the period. Institutional investors own 72.88% of the company’s stock.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.52% on Tuesday, reaching $49.55. 24,530,192 shares of the company’s stock were exchanged. The company has a market capitalization of $82.79 billion, a PE ratio of 28.98 and a beta of 0.75. Bristol-Myers Squibb Co. has a 1-year low of $49.50 and a 1-year high of $77.12. The company has a 50 day moving average price of $56.14 and a 200-day moving average price of $66.76.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.03. The business earned $4.90 billion during the quarter, compared to the consensus estimate of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.53 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 87.36%.

BMY has been the subject of several research reports. Jefferies Group lifted their price objective on shares of Bristol-Myers Squibb from $76.00 to $78.00 and gave the company a “hold” rating in a research note on Tuesday, June 14th. Deutsche Bank AG restated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, June 15th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $78.79 price objective for the company in a research note on Monday, June 27th. Goldman Sachs Group Inc. restated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, July 6th. Finally, Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, July 11th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $69.31.

In related news, Director Lamberto Andreotti sold 23,200 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $59.17, for a total transaction of $1,372,744.00. Following the completion of the sale, the director now owns 364,999 shares in the company, valued at approximately $21,596,990.83. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.